Moneycontrol
HomeNewsBusinessMarketsMaharashtra lockdown to shave off 0.3% growth; opportunity for long-term investors to buy: Experts
Trending Topics

Maharashtra lockdown to shave off 0.3% growth; opportunity for long-term investors to buy: Experts

Large market corrections provide good investment opportunities to both existing and new investors. Investors always wish to buy low, but when the markets fall, they panic and hardly act, suggest experts.

April 06, 2021 / 09:43 IST
Story continues below Advertisement

Few countries have escaped a second wave of the COVID-19 pandemic and it is India’s turn now as active cases topped 1,00,000 as of April 5, which resulted in some knee-jerk reaction in Indian markets on Monday.

Story continues below Advertisement

Of the 1,00,000 new COVID-19 cases, 57,000 came from Maharashtra. The Maharashtra government on April 4 announced new restrictions under its ‘Break the Chain’ campaign to curb the spread of novel coronavirus infections which will last till April 30.

The S&P BSE Sensex closed below 50,000 while the Nifty50 breached the 50-Days Moving Average on the downside. However, experts feel that these knee-jerk reactions are good for investors who were sitting on the sidelines to get into markets and buy quality stocks.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show
Much of the rally seen in FY21 was on the back of economic recovery, and in case that takes a hit then earnings growth will also not be able to revive in a way which D-Street is factoring.

According to the data released by the government, over 7.91 crore vaccinations were done to date and the government is using all its resources to ramp up the vaccination drive in the country.

“Investors who are sitting on good profits can look at partial profit booking unless they have built the portfolio for really long term and want to hold on to quality stocks. Also, to initiate any new position, investors should wait for some time as the volatility arising from increasing COVID-19 cases might remain,” Gaurav Garg, Head of Research at CapitalVia Global Research Limited told Moneycontrol.

“Overall, we may expect the market to trade in the range of 14,000-15,350 in the coming sessions. Investors should wait for some time to let the volatility go down a bit and then the investors who wish to invest for the long term may utilise the opportunity to invest in the quality picks,” he said.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.